Evidence map›Paper›PMID 29287587›Full record

ArticleBMC medicine2017

Simulations for designing and interpreting intervention trials in infectious diseases.

M Elizabeth Halloran, Kari Auranen, Sarah Baird, Nicole E Basta, Steven E Bellan, Ron Brookmeyer, Ben S Cooper, Victor DeGruttola, James P Hughes, Justin Lessler and 9 more

Abstract read
In one paragraph

Article in BMC medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Observational
  17. Dynamical Modeling as a Tool for Inferring Causation.American journal of epidemiology · 2022
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

M Elizabeth HalloranVaccine and Infectious Disease Division, Fred Hutchinson Research Center, 1100 Fairview Ave N, Seattle, WA, 98109, USA. betz@fhcrc.org.ORCID 0000-0002-3127-1757
Kari AuranenDepartment of Mathematics and Statistics, University of Turku, Turku, Finland.
Sarah BairdDepartment of Global Health, Milken Institute School of Public Health, The George Washington University, Washington DC, USA.
Nicole E BastaDivision of Epidemiology and Community Health, School of Public Health, University of Minnesota, Minneapolis, MN, USA.
Steven E BellanDepartment of Epidemiology and Biostatistics, College of Public Health, University of Georgia, Athens, GA, USA.
Ron BrookmeyerDepartment of Biostatistics, The Fielding School of Public Health, UCLA, Los Angeles, CA, USA.
Ben S CooperMahidol Oxford Tropical Medicine Research Unit, Bangkok, Thailand.
Victor DeGruttolaDepartment of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
James P HughesDepartment of Biostatistics, School of Public Health, University of Washington, Seattle, WA, USA.
Justin LesslerDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Eric T LofgrenPaul G. Allen School for Global Animal Health, Washington State University, Pullman, WA, USA.
Ira M LonginiDepartment of Biostatistics, University of Florida, Gainesville, FL, USA.
Jukka-Pekka OnnelaDepartment of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
Berk ÖzlerDevelopment Research Group, The World Bank, Washington DC, USA.
George R SeageDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
Thomas A SmithDepartment of Epidemiology and Public Health, Swiss Tropical & Public Health Institute, Basel, Switzerland.
Alessandro VespignaniNetwork Science Institute, Northeastern University, Boston, MA, USA.
Emilia VynnyckyModelling and Economics Unit, Public Health England, Colindale, UK.
Marc LipsitchDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA.

Funding

UCLA Rapid, Relevant, Rigorous Implementation Science HubP30MH058107 · NIMH · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Nina Thawata Harawa · 1997 to 2026
$53.5M
Understanding and controlling antibiotic resistanceU54GM088558 · NIGMS · HARVARD SCHOOL OF PUBLIC HEALTH · PI LIPSITCH, MARC · 2009 to 2018
$26.4M
Understanding Transmission with Integrated Genetic and Epidemiologic InferenceU54GM111274 · NIGMS · FRED HUTCHINSON CANCER RESEARCH CENTER · PI VESPIGNANI, ALESSANDRO · 2014 to 2018
$12.5M
STATISTICAL ISSUES IN AIDS RESEARCHR01AI029168 · NIAID · UNIVERSITY OF WASHINGTON · PI HUGHES, JAMES P · 1989 to 2018
$5.3M
Methods for Evaluating Vaccine EfficacyR37AI032042 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI HALLORAN, M ELIZABETH · 2010 to 2019
$5.1M
Antibody persistence after conjugate meningococcal group A vaccination in MaliDP5OD009162 · OD · UNIVERSITY OF WASHINGTON · PI BASTA, NICOLE ELAINE · 2011 to 2015
$1.9M
Calibration and Simulation of the Botswana Combination Prevention ProjectR01GM116525 · NIGMS · HARVARD SCHOOL OF PUBLIC HEALTH · PI SEAGE, GEORGE R · 2015 to 2017
$1.5M
Integrative Modeling of study design and transmission dynamics to infer epidemic drivers and inform decision-making: Applications to HIV and other emerging pathogensK01AI125830 · NIAID · UNIVERSITY OF TEXAS AT AUSTIN · PI BELLAN, STEVEN E · 2016 to 2018
$397k
Medical Research Council MR/K006924/1NIAID NIH HHS K01 AI125830NIAID NIH HHS R01 AI029168NIAID NIH HHS R37 AI032042NIGMS NIH HHS R01 GM116525NIGMS NIH HHS U54 GM088558NIGMS NIH HHS U54 GM111274NIH HHS DP5 OD009162NIH HHS DP5OD009162NIMH NIH HHS P30 MH058107Wellcome TrustWellcome Trust 106698/Z/14/Z
6 · The paper itself

Abstract

backgroundInterventions in infectious diseases can have both direct effects on individuals who receive the intervention as well as indirect effects in the population. In addition, intervention combinations can have complex interactions at the population level, which are often difficult to adequately assess with standard study designs and analytical methods. DISCUSSION: Herein, we urge the adoption of a new paradigm for the design and interpretation of intervention trials in infectious diseases, particularly with regard to emerging infectious diseases, one that more accurately reflects the dynamics of the transmission process. In an increasingly complex world, simulations can explicitly represent transmission dynamics, which are critical for proper trial design and interpretation. Certain ethical aspects of a trial can also be quantified using simulations. Further, after a trial has been conducted, simulations can be used to explore the possible explanations for the observed effects.

conclusionMuch is to be gained through a multidisciplinary approach that builds collaborations among experts in infectious disease dynamics, epidemiology, statistical science, economics, simulation methods, and the conduct of clinical trials.

Indexed as

Clinical Trials as TopicComputer SimulationResearch DesignCommunicable DiseasesHumansClinical trial designInfectious diseasesMathematical modelingSimulationsVaccine

Identifiers

PMID29287587
PMCPMC5747936

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.